Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;5(9):100632.
doi: 10.1016/j.lanhl.2024.08.001. Epub 2024 Sep 13.

SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?

Pasquale Mone  1 , Michele Ciccarelli  2 , Stanislovas S Jankauskas  3 , Germano Guerra  4 , Carmine Vecchione  2 , Valeria Visco  2 , Gaetano Santulli  5
Affiliations

SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?

Pasquale Mone et al. Lancet Healthy Longev. 2024 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no conflicting interests.

References

    1. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013; 381: 752–62. - PMC - PubMed
    1. Mone P, Lombardi A, Gambardella J, et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 2022; 45: 1247–51. - PMC - PubMed
    1. Kutz A, Kim DH, Wexler DJ, et al. Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes. Diabetes Care 2023; 46: 2004–14. - PMC - PubMed
    1. Santulli G, Varzideh F, Forzano I, et al. Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart. Hypertension 2023; 80: 1800–09. - PMC - PubMed
    1. Hsiao FY, Tan EC, Meng LC, et al. Impact of frailty on effectiveness and safety of GLP-1 receptor agonist and SGLT2 inhibitor in people with type 2 diabetes: a nationwide longitudinal study. Lancet Healthy Longev 2024. 10.1016/j.lanhl.2024.07.004 (in press). - DOI - PubMed

MeSH terms

Substances